<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00169910</url>
  </required_header>
  <id_info>
    <org_study_id>P05.105</org_study_id>
    <nct_id>NCT00169910</nct_id>
  </id_info>
  <brief_title>VIP: Vascular Imaging Project. Study on the Progression of Cardiovascular Disease in Renal Transplant Recipients</brief_title>
  <official_title>VIP: Vascular Imaging Project. Prospective Randomized Study on the Effect of AUC-monitored Treatment With Steroids Combined With Either a Calcineurin Inhibitor or Mycophenolate Mofetil on the Progression of Subclinical Cardiovascular Disease in Renal Transplant Recipients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Leiden University Medical Center</source>
  <brief_summary>
    <textblock>
      This is a prospective randomized study to compare the influence of area under the curve&#xD;
      (AUC)-monitored dual treatment with steroids in combination with either a calcineurin&#xD;
      inhibitor (CNI) or mycophenolate mofetil (MMF) on the progression of subclinical&#xD;
      cardiovascular disease in renal transplant recipients.&#xD;
&#xD;
      Since CNI have a detrimental effect on cardiovascular risk factors, it is the researchers'&#xD;
      hypothesis that renal recipients after CNI withdrawal will have more reduction of markers of&#xD;
      cardiovascular disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stable renal transplant patients on maintenance immunosuppressive therapy with steroids, a&#xD;
      calcineurin inhibitor (CNI) and mycophenolate mofetil (MMF) will be randomized for&#xD;
      AUC-monitored withdrawal of either CNI or MMF.&#xD;
&#xD;
      The progression of cardiovascular markers will be assessed by yearly measurements of Intima&#xD;
      Media Thickness, Pulse Wave Velocity and Left Ventricular Hypertrophy in both groups.&#xD;
&#xD;
      The duration of the study will be 3 years and the target sample size is 100 patients per arm&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary endpoint: progression of subclinical cardiovascular disease as assessed by intima media thickness (IMT), pulse wave velocity (PWV) and left ventricular hypertrophy (LVH)</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary endpoint: Cardiovascular risk factors: a) Hypertension, b) Hyperlipidemia, c) Diabetes mellitus/glucose intolerance</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft function</measure>
    <time_frame>1 year, 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute rejection</measure>
    <time_frame>1 year, 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft survival (creatinine clearance &lt; 15 ml/min or dialysis)</measure>
    <time_frame>1 year, 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">119</enrollment>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AUC monitored withdrawal of MMF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AUC monitored withdrawal of CNI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AUC monitored withdrawal of MMF or CNI</intervention_name>
    <description>AUC monitored withdrawal of MMF or CNI from a immunosuppressive drug regimen with steroids, CNI and MMF in stable renal transplant recipients</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients, 18 years or older, on triple maintenance therapy with cyclosporine or&#xD;
             tacrolimus , MMF and steroids&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Calculated creatinine clearance &lt; 30 ml/min&#xD;
&#xD;
          -  Multi-organ recipients&#xD;
&#xD;
          -  Patients with a (historic) panel reactive antibody (PRA) &gt;60%&#xD;
&#xD;
          -  Third renal transplant or more.&#xD;
&#xD;
          -  Patients receiving investigational drugs other than MMF in combination with&#xD;
             cyclosporine or tacrolimus&#xD;
&#xD;
          -  Solid malignancy, post-transplant lymphoproliferative disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johan W. de Fijter, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2300 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Schnuelle P, van der Heide JH, Tegzess A, Verburgh CA, Paul LC, van der Woude FJ, de Fijter JW. Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen. J Am Soc Nephrol. 2002 Feb;13(2):536-543. doi: 10.1681/ASN.V132536.</citation>
    <PMID>11805185</PMID>
  </reference>
  <reference>
    <citation>O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med. 1999 Jan 7;340(1):14-22.</citation>
    <PMID>9878640</PMID>
  </reference>
  <reference>
    <citation>Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness on survival in end-stage renal disease. Circulation. 1999 May 11;99(18):2434-9.</citation>
    <PMID>10318666</PMID>
  </reference>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>December 13, 2012</last_update_submitted>
  <last_update_submitted_qc>December 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Leiden University Medical Center</investigator_affiliation>
    <investigator_full_name>J.S.Mourer</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Renal Transplantation</keyword>
  <keyword>Calcineurin Inhibitor</keyword>
  <keyword>Mycophenolate Mofetil</keyword>
  <keyword>Cardiovascular Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

